"
Team:SupBiotech-Paris/Acknowledgement
From 2009.igem.org
(Difference between revisions)
| Line 10: | Line 10: | ||
|'''UMR8121 from the Gustave Roussy Institute''' | |'''UMR8121 from the Gustave Roussy Institute''' | ||
|- | |- | ||
| - | | | + | | |
|} | |} | ||
| - | *Lluis Mir | + | |
| - | *Karim | + | Thanks a lot to: |
| + | |||
| + | **Lluis M. Mir | ||
| + | **Karim Benihoud | ||
'''Our Sponsors''' | '''Our Sponsors''' | ||
| - | * | + | **Embassy of France in Washington [http://fr.ambafrance-us.org/spip.php?rubrique=[Link]] |
| - | * | + | **Eurogentec [http://www.eurogentec.com/eu-home.html [Link]] |
| - | * | + | **Takara [http://www.takarabioeurope.com/ [Link]] |
| - | * | + | **Clonetec [http://www.clontech.com/ [Link]] |
| - | * | + | **Promega [http://www.promega.com/ [Link]] |
| - | * | + | **Sigma-Aldrich [http://www.sigmaaldrich.com/ [Link]] |
| - | * | + | **Qiagen [http://www1.qiagen.com/ [Link]] |
Revision as of 14:20, 19 August 2009
Project
Introduction Current therapies Gene therapies DVS Concept Tissue Vector Cell Vector Therapeutic plasmid Conclusion Implementation Tissue targeting Antitumor action Treatment modeling Conclusion
Ressources
BioBricks Material & Method Bibliography
Ethics & Safety
| We want to acknowledge : |
| UMR8121 from the Gustave Roussy Institute |
Thanks a lot to:
- Lluis M. Mir
- Karim Benihoud
Our Sponsors
- Embassy of France in Washington [http://fr.ambafrance-us.org/spip.php?rubrique=[Link]]
- Eurogentec [http://www.eurogentec.com/eu-home.html [Link]]
- Takara [http://www.takarabioeurope.com/ [Link]]
- Clonetec [http://www.clontech.com/ [Link]]
- Promega [http://www.promega.com/ [Link]]
- Sigma-Aldrich [http://www.sigmaaldrich.com/ [Link]]
- Qiagen [http://www1.qiagen.com/ [Link]]
